Sanofi Ventures doubles down on early-stage biotech with $625M boost
As venture capital for early-stage biotech companies becomes increasingly limited, Sanofi is choosing to go against the grain. Through its investment arm Sanofi Ventures...
Big Pharma
Bioteknik
Premium